TY - JOUR
T1 - Variation in clinical application of hyperthermic intraperitoneal chemotherapy
T2 - A review
AU - Helderman, Roxan F.C.P.A.
AU - Löke, Daan R.
AU - Kok, H. Petra
AU - Oei, Arlene L.
AU - Tanis, Pieter J.
AU - Franken, Nicolaas A.P.Klaas
AU - Crezee, Johannes
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Peritoneal metastasis (PM) originating from gastrointestinal and gynecological malignancies are associated with a poor prognosis and rapid disease progression. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an effective treatment option with curative intent. Hyperthermia enhances the cytotoxicity of chemotherapeutic drugs, thereby killing microscopic tumors and reducing the risk of tumor recurrence. Eight parameters potentially have an impact on the efficacy of HIPEC: the type of drug, drug concentrations, carrier solution, volume of the perfusate, temperature of the perfusate, duration of the treatment, the technique of delivery, and patient selection. In this review, a literature search was performed on PubMed, and a total of 564 articles were screened of which 168 articles were included. Although HIPEC is a successful treatment, there is no standardized method for delivering HIPEC: the choice of parameters is presently largely determined by institutional preferences. We discuss the current choice of the parameters and hypothesize about improvements toward uniform standardization. Quantifying the effect of each parameter separately is necessary to determine the optimal way to perform HIPEC procedures. In vivo, in vitro, in silico, and other experimental studies should shed light on the role of each of the eight parameters.
AB - Peritoneal metastasis (PM) originating from gastrointestinal and gynecological malignancies are associated with a poor prognosis and rapid disease progression. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an effective treatment option with curative intent. Hyperthermia enhances the cytotoxicity of chemotherapeutic drugs, thereby killing microscopic tumors and reducing the risk of tumor recurrence. Eight parameters potentially have an impact on the efficacy of HIPEC: the type of drug, drug concentrations, carrier solution, volume of the perfusate, temperature of the perfusate, duration of the treatment, the technique of delivery, and patient selection. In this review, a literature search was performed on PubMed, and a total of 564 articles were screened of which 168 articles were included. Although HIPEC is a successful treatment, there is no standardized method for delivering HIPEC: the choice of parameters is presently largely determined by institutional preferences. We discuss the current choice of the parameters and hypothesize about improvements toward uniform standardization. Quantifying the effect of each parameter separately is necessary to determine the optimal way to perform HIPEC procedures. In vivo, in vitro, in silico, and other experimental studies should shed light on the role of each of the eight parameters.
KW - Colorectal cancer (CRC)
KW - Cytoreductive surgery
KW - HIPEC
KW - Peritoneal carcinomatosis
KW - Peritoneal metastasis
UR - http://www.scopus.com/inward/record.url?scp=85061985325&partnerID=8YFLogxK
U2 - https://doi.org/10.3390/cancers11010078
DO - https://doi.org/10.3390/cancers11010078
M3 - Review article
C2 - 30641919
SN - 2072-6694
VL - 11
JO - Cancers
JF - Cancers
IS - 1
M1 - 78
ER -